Tonghua Jinma (000766) announced that its wholly-owned subsidiary Harbin Sanctity Biological Pharmaceutical Co., Ltd. (hereinafter referred to as “Shengtai Bio”) and Chengdu Yonkon Pharmaceutical Co., Ltd. (hereinafter referred to as “Yongkang Pharma”) will jointly contribute a total value of $17.4 million to acquire a 100 percent stake of Anyang Yuanshou Biological Pharmaceutical Co., Ltd. (abbreviated as “Yuan Shou Bio”) from its shareholders Gongqingcheng Shusheng Investment Partnership (Limited Partnership), Xue Shaojun, and Wang Qingxun. Tonghua Jinma said that the Yuanshou Bio’s main products are biological, such as live Bacillus cereus tablets and Bacillus cereus capsules, which are exclusive products in China’s probiotic market. They have unique features such as no need of cold-chain logistics, combinational use with antibiotics, biological oxygen capture effect, etc. After the completion of the acquisition, the company's existing platform can be used to effectively integrate related business resources, further extend the company's industrial chain, expand the company's biological product scale, and increase market share.
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
